Skip to main content
S&P 5007,651.54-0.25%DOW50,906.05-0.86%NASDAQ26,861.06+0.24%BTC$83,471.00+0.14%ETH$2,685.00+0.65%GOLD$4,174.70-0.29%OIL$90.33-0.10%
Smart Investors Daily
SID Premium
HC

NASDAQ · HCWB

HCW Biologics Inc.

Healthcare · Biotechnology

$1.71

Down-$0.04 (-2.29%)

Updated Oct 1, 2026, 4:48 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.25M
P/E ratio
-0.2
Dividend yield
0.00%
52-week range
$0.25 – $7.08
Volume
48.41K
Avg. volume
480.27K

Price performance · HCWB

HCWB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 30, 2026

HCWB closed at $1.71 after 20 trading sessions, down 49.03% for the selected period.

Last close
$1.71
Period change
-49.03%
Period low
$1.66
Period high
$3.36
Daily close
View OHLC price history
HCWB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 30, 2026$1.77$1.8227$1.71$1.7148.41K
Sep 29, 2026$1.81$1.85$1.75$1.7552.06K
Sep 28, 2026$1.86$1.895$1.71$1.82104.53K
Sep 25, 2026$1.88$2.00$1.81$1.93418.79K
Sep 24, 2026$1.69$3.12$1.67$1.9913.67M
Sep 23, 2026$1.81$1.83$1.6101$1.66161.35K
Sep 22, 2026$1.91$1.98$1.70$1.81133.71K
Sep 21, 2026$1.95$2.02$1.87$1.9159.23K
Sep 18, 2026$2.00$2.1503$1.87$1.8787.62K
Sep 17, 2026$2.05$2.0743$1.94$1.9567.7K
Sep 16, 2026$2.09$2.10$1.89$2.0186.47K
Sep 15, 2026$2.17$2.1891$2.05$2.0555.47K
Sep 14, 2026$2.2401$2.325$2.18$2.20100.02K
Sep 11, 2026$2.43$2.445$2.16$2.2494.71K
Sep 10, 2026$2.42$2.52$2.41$2.4331.76K
Sep 9, 2026$2.44$2.53$2.34$2.46102.29K
Sep 8, 2026$2.52$2.72$2.10$2.513.09M
Sep 4, 2026$2.81$2.97$2.80$2.9437.3K
Sep 3, 2026$3.34$3.34$2.7001$2.87127.59K
Sep 2, 2026$3.54$3.81$3.32$3.355210.75K

Latest HCWB news

The latest Smart Investors Daily articles mentioning HCWB.

Stock researchCompany · Overview

HCWB research

Overview

Company profile and research snapshot.

Company profile

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HCWB recent ratings
DateFirmRatingTarget
May 28, 2026Maxim GroupBuy—
May 29, 2025Maxim GroupBuy—
Apr 19, 2023EF HuttonBuy—
Mar 30, 2023EF HuttonBuy—
Mar 23, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 24, 2026

HCW Biologics Announces Pricing of $1.5 Million Private Placement

MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”). Pursuant to a securities purchase agreement entered into on Sept

Yahoo · Sep 8, 2026

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By